On April 2, 2026, President Trump issued a proclamation imposing tariffs on patented pharmaceutical imports under Section 232 of the Trade Expansion Act of 1962, establishing a binary governance choice for pharmaceutical manufacturers, medical device companies, and healthcare systems: onshore production by April 2, 2030 to obtain a 20 percent tariff rate, enter an HHS pricing agreement to achieve 0 percent, or absorb a 100 percent ad valorem tariff beginning July 31, 2026. The decision is neither abstract nor distant. It is immediate and irreversible.
Boards of directors in the pharmaceutical, biotech, and medical device sectors are facing an action item that will consume capital allocation decisions, supply chain strategy, manufacturing footprint, and risk exposure for four years. This is not a matter for external compliance teams. The board must engage with the specifics—the tariff architecture, the effective dates, the approval process for onshoring plans, and the financial consequences of each pathway—before management commits the company to a strategy.
What the Section 232 Pharmaceutical Tariffs Actually Do
The proclamation imposes a base rate of 100 percent ad valorem duty on patented pharmaceuticals and active pharmaceutical ingredients (APIs) imported into the United States. This rate takes effect July 31, 2026, for companies listed in Annex III and September 29, 2026, for all others.
The proclamation does not apply a flat tax. Instead, it establishes a tiered structure with two alternative pathways to lower rates. A company importing patented pharmaceuticals or APIs produced by itself or an approved supplier may qualify for a 20 percent tariff rate if it submits and obtains Commerce Secretary approval for an “onshoring plan”—a commitment to manufacture the product or ingredient in the United States. This 20 percent rate remains in place for four years, until April 2, 2030, at which point it reverts to 100 percent unless production is complete.
A second pathway exists through the HHS Medicare/Medicaid pricing agreement (the “MFN” agreement). Companies that execute an approved pricing agreement with the Department of Health and Human Services receive a 0 percent tariff rate on Section 232-covered products, running through January 20, 2029.
Generic pharmaceuticals, biosimilars, and orphan drugs are currently exempt from the tariff. The proclamation mandates a formal review of generic drug treatment within one year.
The Board-Level Decision Window
The decision window is not four years. It is now.
For any company considering the onshoring pathway, Commerce will publish criteria for qualifying plans in the Federal Register. Plans require Commerce approval and are subject to ongoing monitoring and enforcement. A company that files an onshoring plan commits to specific manufacturing milestones and is obligated to submit periodic progress reports to Commerce. A company that misses milestones or commits fraud in reporting faces retroactive tariff imposition and additional penalties.
For a large pharmaceutical manufacturer, onshoring production of a single active pharmaceutical ingredient or finished product requires site selection, facility design, capital investment, regulatory approval from the FDA, and operational ramp-up—typically 18 to 36 months. Some companies will lack U.S. manufacturing capacity and must build it. Competitors for construction labor, equipment, and materials are likely. Cost inflation for manufacturing facility construction is already evident in 2026 projections.
The HHS pricing agreement pathway is time-limited. Agreements run only through January 20, 2029. After that date, a company without an approved onshoring plan reverts to the 100 percent tariff. A company must negotiate and execute an HHS agreement in the next eight months to secure any tariff protection beyond July 2026.
For a company that chooses to absorb the 100 percent tariff without onshoring or HHS agreement, the financial impact materializes immediately. A 100 percent tariff on imported APIs or finished pharmaceuticals doubles the landed cost of the product. For imported inputs that represent 30 percent of the COGS of a pharmaceutical product, the tariff adds 30 percentage points to cost. For a product already operating at slim margins due to Medicare price negotiations, that addition is not absorable. The company will be forced to raise prices, reduce sales, or withdraw from the market.
Supply Chain Reconfiguration and Competitive Advantage
The proclamation converts tariff policy into a supply chain competition. The company that secure Commerce approval for an onshoring plan first and executes construction at lower cost will own a four-year cost advantage: 20 percent tariffs versus 100 percent for competitors. The company that negotiates an HHS pricing agreement avoids tariffs entirely until 2029, a three-year advantage worth tens of millions in pharmaceutical margins.
Competitors that fail to secure either pathway and import patented pharmaceuticals face immediate margin compression. If the company cannot raise prices—because of Medicare negotiations, competition, or market resistance—it must restructure manufacturing, source from new suppliers, or exit product lines. In concentrated markets with few competitors, the cost advantage of onshoring or HHS agreement translates directly to market share.
The board must ask: If onshoring is strategically sound, is our company prepared to move first and lock in a Commerce approval before competitors exhaust available capital and labor? If HHS agreement is feasible, has management opened negotiations with HHS and validated the commercial terms? If neither is viable, which product lines will the company defend at 100 percent tariff, and which will it abandon?
The Governance Imperative
The board’s fiduciary duty requires engagement on several fronts. First, the board must ensure management has completed a product-level and supply-chain-level tariff impact assessment—identifying which products import patented pharmaceuticals or APIs subject to the tariff, quantifying the incremental cost of a 100 percent tariff to COGS and gross margin, and modeling the financial impact across three scenarios: 100 percent tariff, 20 percent tariff (onshoring), and 0 percent (HHS agreement). This assessment must extend beyond pharmaceuticals to medical device companies that import finished devices or key components.
Second, the board must verify that management has identified the compliance deadline for onshoring plan submission to Commerce and the deadline for HHS pricing agreement negotiation. Both are within months, not years. If management has not yet opened negotiations with HHS or retained legal counsel to prepare an onshoring plan filing, the board must understand why and set explicit accountability.
Third, the board must understand the capital and operational requirements of the chosen pathway. Onshoring requires facility investment, FDA approval timelines, and operational execution risk. HHS pricing agreements carry pricing pressure and potential reputational implications. Absorbing a 100 percent tariff requires pricing power or market exit strategy. The board must ensure management has war-gamed each scenario and is prepared for the consequences.
Fourth, the board must establish monitoring and enforcement. If management pursues onshoring, the board should receive quarterly updates on construction progress, regulatory approval status, and cost overruns. If HHS agreement is the strategy, the board should track negotiation status and pricing outcome. The governance failure is silence: permitting management to operate under tariff exposure without explicit board visibility and accountability.
The Section 232 pharmaceutical tariff proclamation is not a compliance task. It is a strategic inflection point that demands board engagement, financial modeling, and governance oversight. The decision window is open for weeks, not months. The consequences last four years. The board that moves decisively—and that demands management identify and execute a tariff strategy—protects shareholder value and enterprise resilience. The board that defers this work to operations and compliance teams will discover in Q3 2026 that the company is uncompetitive and the damage is irreversible.